Frequency Therapeutics reports positive results from hearing loss study

Frequency Therapeutics (NASDAQ:FREQ) reported results from its Phase 2a clinical study of FX-322 for the treatment of sensorineural hearing loss (SNHL). 

The study follows a Phase 1/2 trial that demonstrated statistically significant improvements in word recognition scores in patients with SNHL who received a single intratympanic dose of FX-322, compared to placebo.

Four of the patients that had statistically significant word recognition scores during the Phase 1/2 trial maintained those improvements in the Phase 2a study, with three of these patients remaining at statistically significant levels.

“In addition to a favorable safety profile, we have generated compelling cochlear drug delivery data, and these newly presented results show that the FX-322 benefit to hearing loss may provide individuals with a long-lasting clinical benefit,” David Lucchino, Frequency’s CEO, said in a statement.

“Furthermore, we believe this provides additional evidence supporting the regenerative mechanism of our novel therapeutic approach and a potentially disease modifying treatment,” he added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.